Join Dr Ross Camidge and Dr Mark Socinski as they share insights into the selection of precision therapy for NSCLC based on tumor biomarkers and driver mutations, and strategies to proactively address treatment-related adverse events.

Click here to access this 30-minute activity worth 0.50 / AMA PRA Category 1 Credit(s)^TM

https://www.mycme.com/courses/precision-medicine-in-non-small-cell-lung-carcinoma-new-paradigms-and-best-practices-in-targeted-therapy-7664